Amgen (AMGN): next trial readout expected around 2026-08-19

Catalyst timeline

Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything AMGN is running — see methodology.

1. 2026-08-19todayA Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
2. 2026-08-26in 7dEffect of Maridebart Cafraglutide on the Heart's Electrical Activity
3. 2026-09-03in 2wComparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
4. 2026-10-01in 6wSingle and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
5. 2026-10-08in 7wEvaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
6. 2026-10-22in 9wA Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
7. 2026-10-31in 10wA Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
8. 2026-10-31in 10wA Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
9. 2026-10-31in 10wAnvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
10. 2026-11-15in 13wA Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
11. 2026-11-18in 13wEffect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
12. 2026-11-30in 15wA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
13. 2026-12-14in 17wPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
14. 2026-12-17in 17wSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
15. 2026-12-31in 19wStudy Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
16. 2027-01-21in 22wEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
17. 2027-01-21in 22wEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
18. 2027-04-13in 34wStudy of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
19. 2027-04-19in 35wComparison Between ABP 692 and Ocrevus® (Ocrelizumab)
20. 2027-04-27in 36wEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
21. 2027-05-04in 37wStudy to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
22. 2027-06-30in 45wA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
23. 2027-06-30in 45wA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
24. 2027-07-05in 46wStudy Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Pipeline

Status-change history

Every ClinicalTrials.gov change recorded for AMGN's trials — a running history no other tracker shows.

Frequently asked